Novartis AG (LTS:0K9E)
$ 104.7 0 (0%) Market Cap: 209.81 Bil Enterprise Value: 227.95 Bil PE Ratio: 12.53 PB Ratio: 5.07 GF Score: 80/100

Novartis AG at JPMorgan Healthcare Conference Transcript

Jan 09, 2023 / 04:15PM GMT
Release Date Price: $84.63 (-2.18%)
Richard Vosser
JPMorgan Chase & Co, Research Division - Senior Analyst

Welcome to the Novartis presentation at the 41st JPMorgan Healthcare Conference. I'm Richard Vosser, European pharma analyst at JPMorgan. It's my great pleasure to introduce Vas Narasimhan, the CEO of Novartis.

Before I hand over to him for his presentation, I'd just remind you that the -- we will transition after 20 minutes to Q&A in this room, no moving, which is a big round of applause clearly. And there will be microphones. So there'll be people -- so just put up your hand, I'll indicate, and we'll do questions that way. Awesome. Vas, good to see you.

Vasant Narasimhan
Novartis AG - CEO

Thank you, Richard. Hi, everyone. Great to be here back in person at JPMorgan. Novartis has a 250-year history. And throughout that history, we've had to constantly reinvent the company. And most recently, when you think about the creation of Novartis 25 years ago in its current format, we were a health care conglomerate with 8 different units, spanning everything from nutritionals and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot